# Rituximab in Patients With Relapsed or Refractory TTP-HUS

> **NCT00531089** · PHASE2 · UNKNOWN · sponsor: **Hamilton Health Sciences Corporation** · enrollment: 60 (estimated)

## Conditions studied

- Thrombotic Thrombocytopenic Purpura
- Hemolytic Uremic Syndrome

## Interventions

- **DRUG:** Rituximab

## Key facts

- **NCT ID:** NCT00531089
- **Lead sponsor:** Hamilton Health Sciences Corporation
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2007-12
- **Primary completion:** 2011-01
- **Final completion:** 2011-01
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2010-05-19

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00531089

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00531089, "Rituximab in Patients With Relapsed or Refractory TTP-HUS". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT00531089. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*